Indications

Oncology

  • 80+ clinical sites in Poland, Bulgaria, Germany, Romania, Serbia
  • 100+ investigators in oncology
  • Access to drug-naïve patients, fast recruitment

Breast Cancer

  • phase III trial in 200 patients

Prostate Cancer

  • phase II trial in 40 patients with bone metastasis

Pancreatic Cancer

  • phase III trial in 350 patients

Bladder Cancer

  • phase II in 100 patients with bone metastasis

Leukemia

  • phase III trial in 120 patients

Lymphoma

  • phase III trial in 150 patients
  • phase II trial in 70 Non-Hodgkin´s Lymphoma patients

Myeloma

  • PK trial in 100 patients

Solid Tumors

  • phase III trial in 200 patients
  • PK trial in 80 patients